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Abstract
Background: Obesity and type 2 diabetes (T2DM) are associated with increased circulating free fatty acids and
triacylglycerols. However, very little is known about specific molecular lipid species associated with these diseases. In order
to gain further insight into this, we performed plasma lipidomic analysis in a rodent model of obesity and insulin resistance
as well as in lean, obese and obese individuals with T2DM.
Methodology/Principal Findings: Lipidomic analysis using liquid chromatography coupled to mass spectrometry revealed
marked changes in the plasma of 12 week high fat fed mice. Although a number of triacylglycerol and diacylglycerol species
were elevated along with of a number of sphingolipids, a particularly interesting finding was the high fat diet (HFD)-induced
reduction in lysophosphatidylcholine (LPC) levels. As liver, skeletal muscle and adipose tissue play an important role in
metabolism, we next determined whether the HFD altered LPCs in these tissues. In contrast to our findings in plasma, only
very modest changes in tissue LPCs were noted. To determine when the change in plasma LPCs occurred in response to the
HFD, mice were studied after 1, 3 and 6 weeks of HFD. The HFD caused rapid alterations in plasma LPCs with most changes
occurring within the first week. Consistent with our rodent model, data from our small human cohort showed a reduction in
a number of LPC species in obese and obese individuals with T2DM. Interestingly, no differences were found between the
obese otherwise healthy individuals and the obese T2DM patients.
Conclusion: Irrespective of species, our lipidomic profiling revealed a generalized decrease in circulating LPC species in
states of obesity. Moreover, our data indicate that diet and adiposity, rather than insulin resistance or diabetes per se, play
an important role in altering the plasma LPC profile.
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Introduction
Obesity is an escalating health problem that is associated with
chronic diseases including insulin resistance and type 2 diabetes
mellitus (T2DM). Although the precise mechanism linking obesity
to insulin resistance and T2DM are unknown, extensive evidence
suggests that dyslipidemia plays a central role [1]. This is
characterised by an increase in plasma free fatty acids (FFA) and
triacylglycerols (TG) [2,3]. Nonetheless, it is possible that obesity
may impact upon nearly all indices of lipid homeostasis and that
other circulating lipids contribute to the development of insulin
resistance. Little is known about the plasma lipidome in both
human obesity and rodent models of obesity and insulin resistance.
With the introduction of high throughput mass spectometery-
based technologies, it is now possible to perform comprehensive
lipidomic analysis in body fluids such as plasma. Applying this
novel technology to study circulating lipid changes in obesity may
provide valuable information to help elucidate the mechanisms
responsible for the development of T2DM.
To date, only a limited number of studies have examined the
plasma lipidome in obesity [4–7]. The results of a lipidomic screen
in monozygotic twins discordant for obesity showed that
lysophosphatidylcholine (LPC) species were increased while ether
phospholipids were decreased with obesity [6]. While, Graessler
et al. [4] reported that obesity was associated with markedly
increased levels of saturated TG and diacylglycerol (DG) species.
Furthermore, diet-induced weight loss in obese individuals resulted
in a reduction in saturated and short-chain fatty acid-containing
TGs which correlated with improved insulin sensitivity [5].
Interestingly, the level of LPCs was unaltered by weight loss [5].
While these data provide important information on the effect that
obesity has on the plasma lipidome, it is not known whether the
presence of T2DM leads to specific alterations in lipids indepen-
dent of obesity. Although obesity is associated with T2DM, it is
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important to note that not all obese individuals develop T2DM
[8–10]. Therefore, it is important to investigate whether T2DM is
associated with specific changes in the plasma lipidome. Indeed,
identification of these lipid species may help to elucidate the
mechanisms responsible for the progression from obesity to insulin
resistance and T2DM and may uncover biomarkers to identify
obese individuals at risk of developing T2DM.
Investigating mechanisms involved in the progression from
obesity to insulin resistance and T2DM is difficult in humans. An
alternative is to use animal models to gain an insight into the
aetiology of human obesity and insulin resistance. The most
common rodent model is the chronically high-fat fed mouse.
Although routinely used, there is surprisingly little information
regarding the plasma lipidome in this model. In this study, we
performed lipidomic profiling of plasma from mice fed a high fat
diet for 12 week. Further, to examine the temporal changes that
occur in the progression from mild obesity to severe obesity and
insulin resistance, we also performed time course studies in this
model. Our rodent studies revealed that plasma LPCs were
reduced with high fat-feeding. To establish the relevance of these
findings to human obesity and T2DM, we performed analysis of
plasma LPCs from lean, obese and obese T2DM individuals.
Results
Metabolic and Lipidomic Profile of Chronically Fat-fed
Mice
The high fat diet (HFD) increased body and fat mass (P,0.001;
Table 1). Fat-fed mice displayed higher 5 hour fasted blood
glucose (P,0.05) and plasma insulin levels (P,0.001) despite no
change in plasma FFAs. As expected, a number of TG species
were elevated in fat-fed mice (Figure 1). In fact of all lipid species
analysed (Table S1), the largest increases were found in saturated
TG species (3.5–5.5-fold increase) which on average had less than
one double bond per fatty acid moiety (Figure 1). Notable
increases were also found in DG species (Figure 1). In particular,
DG that contained either palmitic (16:0), stearic (18:0) and oleic
acid (18:1) were elevated. Sphingomyelin, ceramide and hexoysl-
ceramide levels were also increased with HFD (Figure 1). The
HFD increased a number of phospholipid species, especially the
PG and BMP species (Figure 1). Of particular interest was the
finding of a generalised reduction in LPCs in the plasma of fat-fed
mice (Figure 1). A number of studies have recently identified a role
for LPCs in regulating glucose metabolism in both a positive and
negative manner [11,12], our subsequent studies therefore focused
on LPCs. As liver, skeletal muscle and adipose tissue play vital
roles in regulating glucose homeostasis and accumulation of
bioactive lipids in these tissues is associated with insulin resistance,
we next determined whether the HFD altered tissue LPC levels. In
liver, the HFD resulted in a significant reduction in the levels of
LPC 20:0 and LPC 20:1 (Figure 2A). Similarly, only modest
changes in the muscle LPC profile was found with decreases in
LPC 16:0 and 20:1 in response to fat feeding (Figure 2B). In
contrast to the observations in liver and muscle, the levels of LPC
17:0, 18:0 and 20:3 were elevated in adipose tissue of mice
maintained on the HFD (Figure 2C). Despite the changes in
molecular species in these tissues, the HFD failed to alter total
LPC levels (Figure 2A–C). Thus, in contrast to our findings in
plasma, only modest changes in tissue LPCs were noted.
Time Course Changes in the Metabolic Parameters and
Plasma LPC Levels during Chronic Fat Feeding
In order to determine when the change in plasma LPCs
occurred in response to the HFD, we performed time course
studies in mice fed a HFD for 1, 3 and 6 weeks. Metabolic
phenotyping was carried out at each of these time points. Body
weight and fat mass were increased after only 1 week of HFD
and were further elevated at 3 and 6 weeks (Figure 3A & B).
Energy intake was increased in mice fed the HFD at week 1
(44.260.4 kJ/d for low-fat diet (LFD) vs 70.862.6 kJ/d for
HFD, P,0.05) and week 3 (48.560.1 kJ/d for LFD vs
91.760.1 kJ/d for HFD, P,0.05). However, at week 6 energy
intake was not different (62.064.8 kJ/d for LFD vs
57.360.3 kJ/d for HFD). Lean mass was not affected by the
HFD (data not shown). Five hour fasted blood glucose was only
elevated after 6 weeks of HFD (Figure 3C) while plasma insulin
levels doubled after 1 week and was further increased at
3 weeks (Figure 3D). However, after 6 weeks of HFD, insulin
levels decreased and were comparable to those following 1 week
of HFD (Figure 3D). Whole body glucose intolerance developed
after 1 week of HFD (Figure 3E & F), was unaltered between
weeks 1 and 3 and after 6 weeks of HFD, was worse than that
observed at either week 1 or 3 (Figure 3E & F).
The plasma LPCs that were significantly altered over the
HFD time course are presented in Figure 4. Interestingly, the
HFD resulted in rapid alterations in the plasma LPC profile.
Indeed, when compared with the profile of 12 week fat fed
mice, over 80% of the changes noted at this point were evident
after only 1 week of HFD (Figure 4). Importantly, the direction
of change in the individual plasma LPC species was very similar
to our 12 week HFD data. Specifically, rapid and sustained
decreases in LPC 15:0 (Figure 4A), 16:1 (Figure 4C), 18:1
(Figure 4E), 18:2 (Figure 4F), 20:1 (Figure 4H) and 20:5
(Figure 4J) were detected in fat fed mice, while the decline in
LPC 16:0 (Figure 4B) occurred later in response the HFD.
While the HFD caused a reduction in many LPC species, the
saturated species LPC 18:0 (Figure 4D) and 20:0 (Figure 4G)
were increased after 1 week of HFD, whereas the increase in
LPC 20:4 (Figure 4I) was only detected after 6 weeks. The
changes in each lipid class analysed are presented in Table S2.
Table 1. Metabolic parameters of C57Bl/6 mice fed a low or
high fat diet for 12 wk.
LFD HFD
Body mass (g) 30.361.2 38.161.0b
Lean mass (g) 25.661.0 25.160.5
Fat mass (g) 3.960.4 12.160.8b
% lean mass 84.561.0 66.061.6b
% fat mass 13.061.4 31.661.5
Epididymal fat pad (g) 0.6360.04 1.9760.10b
Subcutaneous fat pad (g) 0.4260.04 1.5860.13b
Blood glucose (mM) 8.560.4 9.460.5a
Plasma insulin (pM) 62.1610.7 401.0694.0b
HOMA-IR 3.060.5 22.565.5a
Plasma free fatty acids (mM) 0.6660.08 0.6260.06
Plasma triglycerides (mM) 0.8060.10 0.9760.07
All measurements were made in 5 hour fasted mice. Data are mean 6 SEM.
aP,0.05 vs Chow;
bP,0.001 vs Chow. LFD, low fat diet; HFD, high fat diet.
doi:10.1371/journal.pone.0041456.t001
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Relationship between Circulating LPC Levels, Insulin
Resistance and Adiposity
To examine the relationship between plasma LPC levels, insulin
resistance (HOMA-IR), adiposity and diet, regression analysis was
performed (Figure 5A–D and Tables S3, S4, S5). The regression
analysis revealed that only three plasma LPC species (LPC 16:1,
LPC 20:0 and LPC 20:1) showed any significant association with
HOMA-IR. However, when diet was included in the model these
associations were lost. We also observed significant associations
between relative adiposity (ie. % body fat) and circulating LPCs
(Figure 5A–D). Again, when diet was included in the model these
associations disappeared (Tables S3, S4, S5).
Clinical Characteristics of the Human Cohort
The clinical characteristics of all subjects are shown in Table 2.
The obese T2DM group was older than both the lean and obese
non-diabetic groups (P,0.05; Table 2). The obese and obese
T2DM groups were matched for body mass and BMI (Table 2)
and both these groups had significantly greater body mass and
BMI compared with the lean group (P,0.05) as intended (Table 2).
Although blood glucose was higher in the obese T2DM group, no
differences were noted in plasma insulin or HOMA-IR (Table 2).
In addition, no differences were found between groups for plasma
TGs, FFA, total, LDL or HDL cholesterol and blood pressure
(Table 2).
Changes in Plasma LPCs in Human Obesity and T2DM
Consistent with our mouse model of obesity, a large number of
LPC species, as well as the total LPC levels, were reduced in the
plasma of obese healthy and obese T2DM groups when compared
with lean individuals (Table 3). Adjustment for age and common
clinical indices of disease did not affect the associations between
these lipids and disease status. Interestingly, we did not find any
differences between the obese and obese T2DM groups even when
direct comparisons were made, suggesting that obesity per se may
play a role in modulating plasma LPC levels. To explore this
possibility, we examined the relationship between LPC species and
indices of metabolic homeostasis (i.e. body mass, BMI, blood
glucose, plasma insulin, FFA, TGs, total, LDL and HDL
cholesterol). This analysis did indeed reveal that plasma LPC
species were negatively associated with body mass (data not shown)
and BMI (Figure 5; Table S6). In addition, significant negative
correlations were found between a number of LPC species and
plasma insulin levels (Table S6). There was no relationship
between plasma LPCs and other indices such as blood glucose,
HOMA-IR and plasma lipids.
Discussion
Dyslipidemia plays an important role in the development of
insulin resistance (1). Although this generally manifests as increases
in circulating FFAs and TGs, it is likely that the content and
composition of a number of other lipid species is altered and
contributes to the pathogenesis of T2DM. In order to gain more
insight into the changes that occur in circulating lipids in obesity,
we performed lipidomic analysis on the chronically fat fed mouse,
a well characterised and highly utilised rodent model of obesity
and insulin resistance. Although we found that exposing mice to
chronic HFD markedly altered the lipidomic profile, the most
striking observation was the generalized reduction in plasma LPC
species. Time course studies revealed that most of these changes in
LPCs occurred within the first week of diet intervention and
coincided with an increase in fat mass and the development of
glucose intolerance and hyperinsulinemia. Consistent with our
rodent model, human studies revealed a widespread reduction in
LPC species in plasma from obese and obese T2DM individuals.
Interestingly, we were unable to detect any differences when
comparing obese individuals with the T2DM patients. Therefore,
our data indicate that obesity-related factors, such as diet and
adiposity, rather than insulin resistance and diabetes per se, may
make the major contribution to the changes in LPC profile
observed.
Animal models are routinely used to study obesity and insulin
resistance, however, little is known about the plasma lipidome in
these models. Our first aim was to examine the plasma lipid profile
of mice fed a HFD for 12 weeks. Fat feeding resulted in marked
changes in the plasma lipid profile (Figure 1) including increases in
a number of TG and DG species. In particular, most of the DG
species that were increased contained either palmitic (16:0); steraic
(18:0) or oleic acid (18:1) which reflects the fatty acid composition
of our HFD. The HFD also caused an increase in a restricted
subset of PC species, but these changes were minor compared with
the magnitude of change in other lipids such as TG. In addition,
the HFD resulted in specific increases in the saturated ceramide
species 18:0, 20:0 and 22:0. These findings are consistent with a
previous report demonstrating that plasma ceramide levels are
elevated in the obese, insulin resistant ob/ob mouse [13].
Furthermore, it has been reported that plasma ceramides are
elevated in T2DM humans [14]. Despite this accumulating data
demonstrating that circulating ceramides are elevated with obesity,
there is no evidence to suggest that plasma ceramides have a
mechanistic role in the development of insulin resistance.
The novel and unexpected finding of this study was the general
trend for LPCs to be reduced in plasma from chronically fat-fed
mice. LPC is an important signalling molecule with diverse
biological functions and is involved in regulating cellular
proliferation, tumour cell invasion and inflammation [15–18]. As
obesity is associated with chronic low-grade inflammation [19],
one may expect LPCs to be increased with obesity. Indeed, plasma
LPCs have been reported to be elevated in obesity [6] and T2DM
[20]. In addition, liver and skeletal muscle LPC levels are
increased in the obese diabetic db/db mouse and lowering tissue
LPCs ameliorated insulin resistance and diabetes in these mice
[11]. Taken together, these findings support the recent notion that
LPC may be involved in mediating insulin resistance in obesity
[11]. However, our results contrast these findings. We clearly show
that 12 weeks of fat feeding, which induces severe obesity, is
associated with a reduction in plasma LPC levels. Our data are in
support of recent studies demonstrating that plasma LPC levels are
reduced in individuals with impaired glucose tolerance [21] and in
a mouse model of steatohepatitis [22]. Thus, evidence is emerging
to indicate that metabolic disorders are associated with a reduction
in plasma LPCs. The mechanism responsible for the reduction in
circulating LPC is unknown but may be due to an increase in
Figure 1. The effect of high-fat diet on the plasma lipidome. Significant mean fold changes (P,0.05) observed in plasma lipids from mice fed
a high fat diet for 12 week (N= 6) relative to low fat fed animals (N = 8). Plasma lipids were analysed by LC ESI-MS/MS and absolute lipid levels were
expressed relative to the low fat fed control group. Plasma samples were obtained from 5 hour fasted animals. BMP, bismonoacylglycerolphosphate;
Cer, ceramide; DG, diacylglycerol; DHC, dihexosylceramide; LPC, lysophosphatidylcholine; MHC, monohexosylceramide; PC, phosphatidylcholine; PE,
phosphatidylethanolamine; PG, phosphatidylglycerol; SM, sphingomyelin; Sph, sphingosine; TG, triacylglycerol; THC, trihexosylceramide.
doi:10.1371/journal.pone.0041456.g001
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Figure 2. Tissue lysophosphatidylcholine levels in low and high fat fed mice. Liver (A), skeletal muscle (B) and adipose tissue (C)
lysophosphatidylcholine (LPC) levels measured by LC ESI-MS/MS in mice fed a low (N=8) or high fat diet (HFD, N= 6). Tissues were collected from
5 hour fasted animals. Data are presented as mean 6 SEM. *P,0.05 versus low fat.
doi:10.1371/journal.pone.0041456.g002
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breakdown or enhanced clearance from the circulation by
metabolically active tissues. We therefore examined the LPC
content of a number of metabolically active tissues (liver, muscle
and adipose) in order to determine whether elevated uptake and
storage of LPC may contribute not only to lower circulating LPC
levels but also to the development of insulin resistance. In contrast
to Han et al. [11], we failed to show that the HFD caused an
increase in LPC content in liver and muscle, the two most
important tissues in regulating insulin sensitivity. In fact, if
anything, we show that the HFD decreased some molecular
species of LPC in these tissues. Adipose tissue is also involved in
regulating metabolism and is a major site of metabolic inflamma-
tion [19,23,24]; thus we examined LPC levels in this tissue.
Consistent with our findings in liver and muscle, total LPC levels
were unaltered in adipose tissue from fat fed mice. However,
unlike liver and muscle, we detected increases in a very small
Figure 3. Time course changes in metabolic parameters measured in mice fed a high fat diet. Body mass (A), fat mass (B), fasting blood
glucose (C), plasma insulin (D), blood glucose during an intraperitoneal glucose tolerance test (E) and blood glucose area under the curve during an
intraperitoneal glucose tolerance test (F) were measured in mice (N= 11) following a 5 hour fast at baseline (time 0) and after 1, 3 and 6 weeks of
high fat feeding. Data are presented as mean 6 SEM. *P,0.05 versus baseline; {P,0.05 versus week 1; {P,0.05 versus week 3.
doi:10.1371/journal.pone.0041456.g003
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number of LPC species. Whether this small increase in such a
restricted subset of LPC species is able to alter the metabolic and
inflammatory profile of adipose tissue and subsequent whole body
insulin sensitivity is not known. Together with the fact that the
inflammatory response initiated in adipose tissue is proposed to
cause insulin resistance by stimulating lipolysis and increasing
circulating FFAs [23] and that the HFD did not alter plasma
FFAs, we speculate that alterations in the adipose LPC profile are
unlikely to contribute to the development of whole body insulin
resistance.
Recent findings also suggest that nutritional status can influence
circulating LPC levels [25]. While Kus et al. [25] reported no
differences in plasma LPCs in the fasted state, upon re-feeding a
number of LPC species (18:0, 18:2 and 20:4) were elevated in high
fat fed mice. Although these findings may have implications for
our study as we collected plasma in the fasted state (5 hour fast),
the fasting conditions used by Kus et al. [25] were much longer
and more extreme (ie. 14 hour fast) than used in the current study.
Such an extended fast is likely to cause many changes that may
alter metabolism including a reduction in body mass and depletion
of liver glycogen content. Nonetheless, these data do provide
evidence that nutritional status can influence circulating LPC
levels and should be a factor taken into consideration when
performing lipidomic profiling.
Our studies of chronically fat-fed mice clearly show that the
presence of obesity and insulin resistance alter the plasma LPC
levels. However, these results do not provide a great deal of insight
into the temporal changes that occur in plasma LPCs in the
development of obesity and insulin resistance. We therefore
performed time course studies to examine when obesity and
insulin resistance develop with the HFD and attempted to identify
whether this is associated with alterations in the plasma LPC
profile. After only one week of HFD, significant increases in
adiposity were found together with a doubling in plasma insulin
despite no change in blood glucose, indicative of the development
of insulin resistance. In addition, mice developed glucose
intolerance. This rapid induction of obesity, hyperinsulinemia
and glucose intolerance was associated with alterations in the
plasma LPC profile. In fact, of all LPC species that were altered
over the 6 week HFD intervention, .80% of these changes were
detected after the first week. An interesting point to note is that
despite further increases in adiposity at 3 and 6 weeks of HFD and
additional deterioration in glucose tolerance at week 6, the plasma
LPC profile remained relatively unchanged after the first week.
Furthermore, the actual changes in the LPC species largely
reflected those alterations we observed with our initial 12 week fat
feeding study.
Despite showing that HFD caused rapid alterations in the
plasma LPC profile, we were unable to dissect out the exact role of
obesity versus insulin resistance in contributing to these changes.
At the earliest time point studied, mice had already gained
significant fat mass which coincided with the development of
glucose intolerance and hyperinsulinemia. Therefore, it is difficult
to examine whether the high fat diet, obesity or insulin resistance
per se is the major factor causing these changes in circulating LPC.
To try to further define this relationship, regression analysis was
performed. This revealed that only a limited number of LPC
species (LPC 16:1, LPC 20:0 and LPC 20:1) were associated with
HOMA-IR. However, when diet was included in the model no
associations were found between HOMA-IR and plasma LPC
species suggesting that diet was more important than insulin
resistance in determining circulating LPC levels. Furthermore, our
analysis revealed that a number of LPC species were associated
with adiposity (ie. % fat mass). Interestingly, these associations
Figure 4. Time course changes in selected lysophosphatidylcholine (LPC) species measured in plasma of mice fed a high fat diet.
LPC 15:0 (A), LPC 16:0 (B), LPC 16:1 (C), LPC 18:0 (D), LPC 18:1 (E), LPC 18:2 (F), LPC 20:0 (G), LPC 20:1 (H), LPC 20:4 (I) and LPC 20:5 (J) were measured in
mice (N= 11) following a 5 hour fast at baseline (time 0) and after 1, 3 and 6 weeks of high fat feeding using LC ESI-MS/MS. Data are presented as
mean 6 SEM. *P,0.05 versus baseline; {P,0.05 versus week 1; {P,0.05 versus week 3.
doi:10.1371/journal.pone.0041456.g004
Figure 5. Relationship between plasma lysophosphatidylcholine (LPC), adiposity and indices of insulin resistance in high fat fed
mice (A–D) and lean, obese and obese type 2 diabetic humans (E–H). The association between circulating LPC and percent body fat (A),
blood glucose (B), plasma insulin (C) and HOMA-IR (D) in high fat fed mice. The association between circulating LPC and BMI (E), blood glucose (F),
plasma insulin (G) and HOMA-IR (H) in the human cohort. Data are presented as line of best fit with 95% confidence intervals.
doi:10.1371/journal.pone.0041456.g005
Plasma Lysophosphatidylcholines in Obesity
PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e41456
tended to disappear when diet was included in these models. Thus,
while adiposity does appear to play a role in determining
circulating LPCs, diet may actually play a more important role.
In order to provide relevance to the human condition, we
examined plasma LPC levels in a small cohort of lean, obese and
obese T2DM individuals. Consistent with our HFD rodent studies,
we observed a general reduction in plasma LPCs from both the
obese non-diabetic and T2DM individuals. Although contrasting
the reports of increased circulating LPC in obesity [6] and T2DM
[23], these results are consistent with those of others who found
that plasma LPCs were diminished in glucose intolerant and
insulin resistant individuals [4,7,21]. Interestingly, we were unable
to detect any differences in the LPC profile when comparing our
obese otherwise healthy individuals with the T2DM patients.
These findings may indicate that adiposity, rather than diabetes
per se, makes the major contribution to the alterations in plasma
Table 2. Subject characteristics.
Lean (N=11) Obese non-diabetic (N=10) Obese type 2 diabetic (N=9)
Age (years) 5162 4963 6062a,b
Height (m) 1.7860.02 1.7860.02 1.7460.02
Body mass (kg) 74.562.1 101.263.9a 95.564.7a
BMI 23.360.4 31.960.4a 31.561.4a
Blood glucose (mM) 5.060.1 4.960.1 8.060.6a,b
Plasma insulin (pM) 36.161.1 60.4613.9 157.6692.4
HOMA-IR 0.760.1 1.160.2 2.060.7
Plasma free fatty acids (mM) 0.2860.05 0.2260.03 0.3360.05
Plasma triglycerides (mM) 1.060.3 1.460.2 1.560.2
Plasma total cholesterol (mM) 4.660.2 4.660.2 5.060.3
Plasma LDL (mM) 2.960.3 2.860.2 2.860.4
Plasma HDL (mM) 1.260.1 1.260.1 1.660.2
Systolic blood pressure (mmHg) 11962 12262 12864
Diastolic blood pressure (mmHg) 7862 7862 7862
Samples were obtained following an overnight (10–12 hour) fast. Data are mean 6 SEM.
aP,0.05 vs lean;
bP,0.05 vs obese non-diabetic.
doi:10.1371/journal.pone.0041456.t002
Table 3. Plasma LPC levels in lean, obese non-diabetic and obese type 2 diabetic individuals.
LPC species (mM) Lean (N=11) Obese non-diabetic (N=10) Obese type 2 diabetic (N=9)
LPC 14:0 0.9260.14 0.7660.10 0.7860.06
LPC 15:0 0.5660.03 0.4660.03a 0.4760.03c
LPC 16:0 34.1161.26 31.5661.14 32.6560.98
LPC 16:1 2.5760.61 1.9760.21 2.2660.40
LPC 18:0 14.3760.54 12.3560.36b 11.9660.56b
LPC 18:1 15.9161.85 11.6360.58a 12.5161.13
LPC 18:2 21.5761.40 16.2560.99b 16.0761.20b
LPC 20:0 0.1060.01 0.0860.01c 0.0660.01b
LPC 20:1 0.2060.03 0.1360.01d 0.1560.01a
LPC 20:2 0.2360.03 0.1460.01 0.1560.01a
LPC 20:3 2.0860.23 1.6460.10 1.6460.16
LPC 20:4 5.4560.39 4.6060.28a 3.8060.35b
LPC 20:5 0.9860.15 0.7660.09 0.7760.11
LPC 22:6 1.5060.16 1.1860.11 1.1560.18
Sum LPC 100.5565.76 83.5362.81a 84.4264.17a
Samples were obtained following an overnight (10–12 hour) fast. Data are mean 6 SEM.
aP,0.05 vs lean;
bP,0.01 vs lean;
cP = 0.052 vs lean;
dP = 0.06 vs lean.
doi:10.1371/journal.pone.0041456.t003
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LPC profile observed. Indeed, significant negative associations
were found to exist between circulating LPCs and BMI. While we
were unable to detect any difference in plasma insulin levels
between groups we did observe a significant negative association
between plasma LPCs and plasma insulin levels. Although our
data lend support to the notion that obesity rather than diabetes
may be the major factor leading to alterations in the plasma LPC
profile, we cannot discount the influence of diet especially given
the results obtained from our animal studies. Unfortunately, we do
not have any information on the dietary habits of the individuals in
our study so we cannot make any conclusions regarding the
association between diet and plasma LPC levels. However, such a
relationship needs to be examined in future studies. While our
study shows that LPCs are reduced in the circulation of obese and
obese T2DM individuals, it is important to note that our analysis
was performed on a very small number of individuals. This
relatively small sample size may have limited our ability to detect
differences between groups. Therefore, further studies using large
cohorts are required to identify if any differences in the plasma
LPC profile exist between obese and obese T2DM individuals and
to further explore the role of diet in influencing LPC levels.
Recently it has been demonstrated that LPC can exert beneficial
effectsonglucosemetabolism[12].Treatingculturedadipocyteswith
LPC stimulated glucose uptake in a dose-dependent manner via an
insulin-independent mechanism involving activation of protein
kinase C d [12]. Furthermore, these authors were also able to show
that acute LPC treatment improved glycemia in mouse models of
diabetes [12]. Thus, LPC may be a novel insulin independent signal
that regulates blood glucose levels [12] and the reduction in
circulating LPC observed in our obese mice and humans may play
some role in contributing to the defects in glucose homeostasis
observed in obesity and T2DM. This notion is particularly important
since the concept of lipids exerting beneficial metabolic effects has
recently received prominence [24].
In conclusion, our data provide evidence that marked changes
occur in the plasma lipidome in the high fat fed mouse model of
obesity. The most striking observation was the generalized
reduction in plasma LPC species in fat fed mice. Our time course
studies revealed that these alterations occur rapidly in response to
fat feeding and coincide with increases in fat mass and the
development of glucose intolerance and hyperinsulinemia. While
our data show that adiposity was associated with LPC levels, diet
appeared to be the most important determinant in these rodent
studies. Consistent with our rodent model, our human data
revealed a widespread reduction in LPC species in plasma from
both obese and obese T2DM individuals. Interestingly, we were
unable to detect any differences when comparing the obese
otherwise healthy individuals with the obese T2DM patients.
Therefore, our data indicate that diet and adiposity, rather than
insulin resistance and diabetes per se, play an important role in
altering the plasma LPC profile.
Materials and Methods
Ethics Statement
All animal experiments were approved by the Alfred Medical
Research and Education Precinct Animal Ethics Committee and
were in accordance with the National Health and Medical
Research Council of Australia Guidelines on Animal Experimen-
tation. The human study was approved by The Alfred Human
Research Ethics Committee and each participant provided written
informed consent.
Changes in Plasma Lipids with Chronic High-fat Feeding
Eight week old male C57Bl/6J mice were obtained in-house
from AMREP Animal Services and were fed either a low fat diet
(LFD; N = 6; 14.3 MJ/kg, 76% of kJ from carbohydrate, 4.5% fat,
19% protein, Specialty Feeds, Glen Forrest, WA, Australia) or
high-fat diet (HFD; N = 8; 19 MJ/kg, 35% of kJ from carbohy-
drate, 42% fat, 23% protein, Specialty Feeds, Glen Forrest, WA,
Australia) for 12 weeks. The fatty acid profile of the diets is
presented in Table S7. Animals were housed in a temperature
controlled room (2261uC) on a 12 hour light/dark cycle with free
access to food and water. Four days prior to completion of the
study, body composition (lean and fat mass) was determined using
the EchoMRI 4-in-1 (Echo Medical Systems, Houston, TX, USA).
At the end of the 12 week diet, mice were fasted for 5 hours and a
blood sample (,50 mL) was obtained, placed in EDTA-tubes and
immediately put on ice. Samples were spun in a centrifuge
(1500 g, 10 min, 4uC) and plasma was stored at 280uC for
subsequent lipidomic and metabolite analysis. Mice were then
anesthetized and tissues (liver, epididymal fat and muscle) were
collected, immediately frozen in liquid nitrogen and stored at
280uC. HOMA-IR was calculated using the following formula:
fasting glucose (mmol/L) 6 fasting insulin (mU/ml)/22.5.
Time Course Changes in Plasma Lipids with High-fat
Feeding
Eight week old male C57Bl/6J mice obtained from AMREP
Animal Services were maintained on a HFD (N = 11) for 6 weeks.
Lean and fat mass was determined prior to the commencement of
the HFD (0 week) and again at 1, 3 and 6 weeks of HFD.
Intraperitoneal glucose tolerance tests (1 g/kg lean body mass)
were performed on 5 hour fasted mice at 0, 1, 3 and 6 weeks of
HFD. Blood samples were obtained from the tail tip at the
indicated times and glucose was measured using a glucometer
(AccuCheck II; Roche, NSW, Australia). For subsequent analysis,
the blood sample (,50 mL) obtained prior to the glucose tolerance
test was placed in EDTA-tubes and immediately stored on ice.
Samples were spun in a centrifuge (1500 g, 10 min, 4uC) and
plasma was stored at 280uC.
Plasma Lipidomic Changes in Human Obesity and T2DM
Plasma samples from 30 male subjects were obtained from the
Baker IDI Heart and Diabetes Institute Biobank. Subjects were
classified as lean (N = 11; BMI,25), obese non-diabetic (N = 10;
BMI.27) or obese T2DM (N = 9; BMI.27). The obese non-
diabetic and obese T2DM groups were matched for body mass
and BMI. Subjects in the obese T2DM group were being treated
with diet (N = 6) or oral hypoglycaemic agents (N = 1 sulfonylurea;
N = 2 metformin). In addition, 3 subjects in the T2DM group were
being treated with anti-hypertensive medication. The T2DM
individuals had no other medical conditions. Apart from those
mentioned above, all were non-medicated and had no known
existing medical conditions. Samples were collected after an
overnight (10–12 hour) fast. Samples were collected from the
antecubital vein into EDTA-vacutainer tubes (Becton Dickinson,
North Ryde, NSW, Australia) and placed on ice. Samples were
spun in a centrifuge (1500 g, 10 min, 4uC) and plasma was
aliquoted and stored at 280uC for subsequent analysis.
Lipidomic Analysis
Lipid analysis was performed by liquid chromatography,
electrospray ionisation-tandem mass spectrometry (LC ESI-MS/
MS) as described previously [26–29]. For tissue lipids, samples
were homogenized in 300 ul 1xPBS, pH 7.47 and protein content
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was determined. Lipids were extracted from 25 mg of protein for
liver, 10 mg of protein for adipose tissue and 50 mg of protein for
muscle. For plasma analysis, lipids were extracted from 10 ml of
plasma. Lipids were extracted using a single-phase chloroform:
methanol (2:1; 20 volumes) extraction following the addition of
internal standards (100 pmol each of ceramide (Cer) 17:0,
glucosylceramide (monohexosylceramide, MHC) 16:0 d3, lacto-
sylceramide (dihexosylceramide, DHC) 16:0 d3 and trihexosylcer-
amide (THC) 17:0 (Matreya Inc., Pleasant Gap, USA), phospha-
tidylcholine (PC) 13:0/13:0, lysophosphatidylcholine (LPC) 13:0,
phosphatidylethanolamine (PE) 17:0/17:0, phosphatidylglycerol
(PG) 17:0/17:0, bismonoacylglycerolphosphate (BMP) 14:0/14:0,
sphingomyelin (SM) 12:0 and sphingosine (Sph) 17:1 (Avanti Polar
Lipids, Alabaster, USA), together with 200 pmol of diacylglycerol
(DG) 15:0/15:0 and 100 pmol of triacylglycerol (TG) 17:0/17:0/
17:0 (Sigma Aldrich). Samples were vortexed, mixed for 10 min
on a rotation mixer, sonicated for 30 min and left to stand at room
temperature for a further 20 min. Extracts were then centrifuged
at 13,000 xg for 10 min, the supernatant was transferred to a
clean tube and dried under nitrogen at 40uC. Lipids were
redissolved in 50 mL water saturated butanol containing 10 mM
NH4COOH then 50 mL methanol containing 10 mM
NH4COOH was added.
Analysis was performed by electrospray ionisation-tandem mass
spectrometry using a PE Sciex API 4000 Q/TRAP mass
spectrometer with a turbo-ionspray source and Analyst 1.5 data
system. Prior liquid chromatographic separation was performed
on a Zorbax C18, 1.8 um, 5062.1 mm column at 300 mL/minute
using the following gradient conditions; 0% B to 100% B over
8.0 minutes followed by 2.5 minutes at 100% B, a return to 0% B
over 0.5 minute then 3.0 minutes at 0% B prior to the next
injection. DGs and TGs were separated using the same system
with an isocratic flow of 15% A/85% B. Solvent A and B consisted
of tetrahydrofuran:methanol:water in the ratios (30:20:50) and
(75:20:5) respectively, both containing 10 mM NH4COOH.
Quantification of individual lipid species was performed using
scheduled multiple-reaction monitoring (MRM) in positive ion
mode. Individual lipid species monitored were the major species
(greater than 1% of total) identified in human plasma. MRM
experiments were based on product ion of m/z 264 [sphingosine–
H2O]
+ for Cer, MHC, DHC and THC, m/z 184 [phosphocho-
line]+ for SM, PC and LPC, m/z 189 [glycerophosphate-NH4]
+
for PG and neutral loss (NL) of 141 Da for PE. DGs and TGs were
monitored by the neutral loss of individual fatty acid species and
BMP by the neutral loss corresponding to the monoacylglycer-
ophosphate moiety. Each ion pair was monitored for 10–50 ms
with a resolution of 0.7 amu at half-peak height and averaged from
continuous scans over the elution period. Lipid concentrations
were calculated by relating the peak area of each species to the
peak area of the corresponding internal standard. Total lipids of
each class were calculated by summing the individual lipid species.
Blood Biochemistry
Plasma insulin was determined by an enzyme-linked immuno-
sorbent assay (Millipore, St. Charles, MO, USA). Plasma FFAs
were measured using an enzymatic colorimetric method (NEFA C
test kit, Wako, Richmond, VA, USA). Plasma TGs, total
cholesterol, LDL and HDL cholesterol were determined using a
Cholestech LDX (Cholestech, Hayward, CA, USA).
Statistical Analysis
For the 12 week HFD study, data were analysed using a
Student’s t-test. Characteristic data are presented as the mean 6
SEM. Lipidomic data are presented as the mean fold change from
the appropriate control group. A value of p,0.05 was considered
statistically significant. For the time course study, data were
analysed using factorial repeated measures ANOVA. The
associations between lipid (LPC species) and diet in mice were
assessed using linear regression with diet (low fat or high fat)
included as a categorical predictor. The influence of HOMA-IR
on the associations was tested by including both diet and HOMA-
IR in the model. For the human study, the associations between
plasma lipids and disease status (lean, obese non-diabetic or obese
T2DM) were assessed using linear regression with disease status
fitted as a categorical predictor. Stepwise regression was also used
to determine whether adjustment for age, total cholesterol, blood
glucose, plasma FFA, insulin, weight or BMI influenced the
associations. A significance value of p,0.05 was used to retain
adjustment variables in the model. Spearman correlation coeffi-
cients were calculated between LPC levels and indices of
metabolic homeostasis.
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